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Background: Angiotensin II acts as a peptide hormone and component of renin-angiotensin- system (RAS) regulating
the blood pressure, and seems to be involved in renal and vascular disorders. There is no reliable quantification method
for angiotensin II available until now and the angiotensin II plasma levels described in the literature are correspondingly
strongly divergent. Therefore, we developed and validated a sensitive, selective and reliable LC-ESI-MS/MS method for
absolute quantification of angiotensin II concentration in human plasma based on the AQUA strategy.
Methods: Plasma samples were extracted using MAX Oasis cartridges and were subjected to a further
immunoaffinity-purification using immobilized anti-angiotensin II antibodies in order to isolate endogenous
angiotensin II. Stable isotope (13C- and 15 N-) labeled angiotensin II was used as an internal standard. The fractionated
samples were analysed using LC-ESI-MS/MS.
Results: The calibration curve was established in plasma in the concentration range 6–240 pM (r2 > 0.999). The
developed and validated method was successfully applied for quantification of endogenous angiotensin II in human
plasma of healthy volunteers and chronic kidney disease (CKD-5D) patients. The mean plasma angiotensin II levels
were found to be 18.4 ± 3.3 pM in healthy subjects and 64.5 ± 32.4 pM in CKD-5D patients (each n =9).
Conclusion: The LC-ESI-MS/MS-based method for quantification of angiotensin II levels in human plasma was
successfully evaluated within the study. This method is applicable for clinical applications aiming at the validation of
the impact of highly physiologically and pathophysiologically active angiotensin II.Introduction
The renin-angiotensin system (RAS) is essential for the
maintenance of blood pressure and fluid balance [1].
The key component of the RAS is the peptide hormone
angiotensin II, which was first isolated in 1939 by Braun-
Menendez and Fasciolo from the renal blood of dogs [2].
This octapeptide with the amino acid sequence Asp-Arg-
Val-Tyr-Ile-His-Pro-Phe is one of the most potent vaso-
constrictors known until now. Angiotensin II has a vaso-
constrictory effect on the efferent arterioles of the kidney.
This leads to an increase of the intraglomerular vascular
resistance, which in turn causes an increased filtration
pressure. Besides the vasoregulatory effect of angiotensin* Correspondence: vjankowski@ukaachen.de
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unless otherwise stated.II, it has been demonstrated that angiotensin II is charac-
terized by proinflammatory, profibrotic and growth stimu-
lating properties [3]. Experimental and clinical studies
have shown angiotensin II affects the progression of
chronic kidney disease (CKD) [4]. Angiotensin II causes
an increased intraglomerular pressure and hyperfiltration
and thus accelerates renal failure. In addition, angiotensin
II affects podocyte function and thus may lead to protein-
uria. This in turn may cause tubulointerstitial inflamma-
tion. Finally, these angiotensin II-mediated changes result
in the histological picture of tubulointerstitial fibrosis
and glomerulosclerosis [5]. Currently, the routine quan-
tification of angiotensin II is performed using antibody-
based fluorescence assays. However, it has been shown
that commercially available monoclonal anti-angiotensin
II-antibodies are characterized by high cross reactivity be-
cause of sequence homologies of different angiotensin pep-
tides [6,7]. Most likely these methodological difficultiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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determined in different studies. These vary in healthy sub-
jects in the range of 3–85 pM [6,8-12].
Mass spectrometry-based methods, using stable isotope-
labeled peptides, allow absolute quantification (AQUA) in
low femtomole range and are especially useful when no
analyte-free matrix is available [13,14]. Therefore, the goal
of this study was the development of a highly selective,
sensitive, accurate and precise method for absolute quanti-
fication of endogenous angiotensin II levels in human
plasma, based on combination of the immunoaffinity-
purification and mass spectrometric detection by using




Standard angiotensin II was purchased from Sigma-
Aldrich (Hamburg, Germany). Stable isotope labeled
angiotensin II (13C and 15 N labeled arginine) was synthe-
sized by Campro Scientific GmbH (Berlin, Germany). MS-
grade water and acetonitrile were purchased from Thermo
Fisher Scientific (Ulm, Germany). MS-grade formic acid,
CN-Br activated sepharose resin beads, protease inhibitor
cocktail and PBS were purchased from Sigma-Aldrich
(Hamburg, Germany). Monoclonal anti-angiotensin II-
antibodies were purchased from Bertin Pharma (Montigny
le Bretonneux, France). Low protein-bind tubes were ob-
tained from Eppendorf (Hamburg, Germany). The Oasis
MAX extraction cartridges were purchased from Waters
(Eschborn, Germany).
Immobilisation of the anti-angiotensin II-antibody
Anti-angiotensin II antibody (80 μg) was diluted in 1 ml
of coupling buffer (0.5 M NaCl, 0.1 M NaHCO3, pH 8.3)
prior to immobilization. Three batches of cyanogen
bromide activated sepharose resin (500 μl) were swollen
in 10 ml of 1 mM cold HCl for 1 hour. The resin was
then washed three times with 10 ml of 1 mM HCl and
three times with 10 ml of coupling buffer. The diluted
antibody was immediately transferred to the washed
resin. The immobilization was carried out 1 h at room
temperature on an overhead rotor. After the immo-
bilization the unbound substrate was washed out three
times using 1.5 ml of blocking buffer (1 M NaCl, 0.05 M
glycine, pH 3.5). The supernatant was removed and the
unbound reactive groups of the sepharose resin were
blocked using blocking buffer 2 h at room temperature.
After the blocking procedure the resin was washed alter-
nately using 1.5 ml of washing buffer 1 (0.5 M NaCl,
0.1 M NaCH3COO, pH 4) and 1.5 ml of washing buffer
2 (0.5 M NaCl, 0.1 M Tris, pH 8). The immobilized anti-
angiotensin II-antibodies were stored in PBS containing
0.02% NaN3 at 4°C until use. Prior to use, the immobilizedanti-angiotensin II-antibodies were washed five times using
1 ml phosphate buffered saline (PBS).
Plasma collection
Peripheral blood (5 ml) from nine healthy volunteers
and nine CKD patients undergoing dialysis (CKD-5D)
was drawn from the cubital vein and was collected in
tubes containing K2-EDTA (1.8 mg/ml). 50 μl of prote-
ase inhibitor cocktail was added immediately after blood
sampling. The blood samples were centrifuged at 2,500 g
for 10 minutes to isolate plasma. The resulting plasma
was prepared as 0.5 ml fractions and 100 fmol of the in-
ternal standard solution (stable isotope (13C- and 15 N-)
labeled angiotensin II) were added to each sample. The
samples were immediately frozen and stored at −20°C
until further sample preparation.
Preparation of calibration standards and quality control
samples
The stock solution of the stable isotope (13C- and 15 N-)
labeled angiotensin II as well as native angiotensin II
were prepared at 100 μM in 1% formic acid in water/
acetonitrile (50/50; v/v) and were stored at −20°C. Only
low protein bind tubes and pipette tips were used, in
order to minimize nonspecific adsorption of the diluted
peptide. The preparation of the calibration samples was
carried out by spiking stable isotope (13C- and 15 N-) la-
beled angiotensin II into plasma at concentration of 6,
15, 30, 60, 120, 240 pM in triplicate. The quality control
samples (QC) were prepared in plasma with stable iso-
tope (13C- and 15 N-) labeled angiotensin II at a concen-
tration of 6 pM for the lower limit of quantification
(LLOQ), at 30 pM for low quality control (LQC), at
120 pM for middle quality control (MQC) and at 240 pM
for high quality control (HQC). The native angiotensin II
was used as an internal standard and was added to the
samples at a final concentration of 200 pM, which corre-
sponds to the endogenous concentration of angiotensin II
in previous studies as well in the present study revealed a
wide range of the angiotensin II concentrations.
Sample preparation
The calibration samples, quality control samples and
plasma samples were prepared in the same approach.
Oasis mixed-mode anion exchange and reversed phase
(MAX) solid phase extraction (SPE) cartridges were used
to remove high molecular plasma compounds and con-
centrate angiotensin II. 0.5 ml plasma were thawed and
diluted with 0.5 ml of 4% phosphoric acid. The extrac-
tion cartridges were preconditioned with 1 ml aceto-
nitrile followed by 1 ml LC-MS grade water. Next, the
sample was loaded. The cartridge was washed with 1 ml
5% ammonium hydroxide followed by 1 ml 10% aceto-
nitrile. The samples were eluted from the SPE cartridge
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was evaporated to dryness, reconstituted with 300 μl
PBS and, if required, the pH was adjusted at 7.4 using
10 M sodium hydroxide. For further immunoaffinity
purification of angiotensin II the extracted samples were
incubated 1 hour at 4°C with 30 μl of immobilized anti-
angiotensin II antibody. Next, the beads were washed
two times using 500 μl PBS. In order to remove all salt the
resin was washed two times using 500 μl LC-MS grade
water. Angiotensin II was eluted three times using 40 μl of
0.1% formic acid directly into the glass vial and evaporated
to dryness. The dried samples were reconstituted in 40 μl
0.1% formic acid and analyzed by ESI-LC-MS/MS.
LC MS/MS analysis
All LC-MS/MS analysis were performed using an Agi-
lent 1200 capillary-HPLC system (Germany) coupled to
a HCT mass-spectrometer (Bruker, Bremen, Germany)
with an electrospray ionisation (ESI) interface. A C18 Aq
Zorbax column (150 × 0.5 mm; 5 μm) was used for sep-
aration. HyStar-software (Bruker, Bremen, Germany)
was used for data acquisition and processing. The mo-
bile phase consisted of 0.1% formic acid in water (mobile
phase A) and 0.1% formic acid in acetonitrile (mobile
phase B). The flow rate was set to 20 μl/min and the in-
jection volume was 40 μl. The column temperature was
maintained at 30°C. The plasma samples were separated
using gradient given in the Table 1. The total time per
run was 25 min. The mass-spectrometer was operated in
the positive ion mode. The source temperature was set
at 300°C. The nebuliser gas was set at 20 psi and the dry
gas flow was 7 l/min. For the detection of angiotensin II,
the MS/MS fragmentation mode was used. The accumula-
tion time was 50 ms. The double charged parent ions of
the native angiotensin II and the stable isotope (13C- and
15 N-) labeled angiotensin II were 523.8 m/z and 528.8 m/z,
respectively. The fragmentation of these ions revealed
for both peptides one dominant fragment ion and sev-
eral low intense ions. The high intense dominant frag-
ment ion was 784.4 m/z for the native angiotensin II
and 794.4 m/z for the stable isotope (13C- and 15 N-)Table 1 LC-gradient used for the separation of the
plasma samples







25 100 0labeled angiotensin II. Therefore, the system was tuned
and optimized for the transition 523.8 m/z - > 784.4
and 528.8 - > 794.4 for the detection of native angioten-
sin II and the internal standard, respectively. Therefore,
the isolation window 526.3 ± 6 m/z was found to be opti-
mal for the detection of both fragment ions. The isola-
tion and the detection of the both ions were performed
within the same scan in order to achieve a high precision
and accuracy. For the MS/MS mode, helium was uses
as the collision gas. For the quantification the extracted
ions chromatograms for the ions 784.4 ± 0.5 m/z and
794.4 ± 0.5 m/z corresponding to the native and stable
isotope (13C- and 15 N-) labeled angiotensin II were gener-
ated and intergraded. Data acquisition and interpretation
was performed by using “Compass 1.3 Software” (Bruker,
Bremen, Germany). Calculations including calibration
curve regressions, sample concentrations values and statis-
tics were performed by using “GraphPad Prism 5.0” soft-
ware (GraphPad Software, San Diego, USA).
Validation procedure
The newly developed method was extensively validated
in terms of selectivity, linearity, intra- and inter-day pre-
cision and accuracy, matrix effects and recovery. All
samples used during validation procedure were taken
from plasma pool from healthy volunteers. All these
samples were pooled before the sample preparation.
Linearity of the calibration
The linearity of the method was determined by analysing
of calibration standards (CS) prepared by spiking pooled
plasma samples using stable isotope (13C- and 15 N-) la-
beled angiotensin II in triplicate. The CS contained 6, 15,
30, 60, 120 and 240 pM of stable isotope (13C- and 15N-)
labeled angiotensin II. The native angiotensin II was used
as an internal standard. The extracted ions chromatograms
for the ions 784.4 ± 0.5 m/z and 794.4 ± 0.5 m/z corre-
sponding to the native and stable isotope (13C- and 15N-)
labeled angiotensin II, were generated and the analyte
peaks intergraded. The concentration curve was con-
structed by plotting the peak-area ratio of stable isotope
(13C- and 15 N-) labeled angiotensin II/native angiotensin
II vs. concentration.
Lower limit of quantification (LLOQ) and limit of
detection (LOD)
The lower limit of quantification (LLOQ) is defined as
the lowest point of the calibration curve with a precision
of CV = 20%. The limit of detection is defined as an
amount giving a signal three times higher than the noise.
Precision and accuracy
The intra- and inter-day precisions and accuracies were
investigated by using quality controls (QC) at 6, 15, 30,
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beled angiotensin II prepared in plasma. The analysis of
the intra-day precision and accuracy was performed in
triplicate on the same day; the inter-day precision and
accuracy were performed on three separate days. The
precision was calculated as the relative standard devi-
ation of the replicates. Accuracy was calculated by com-
parison of the measured concentration of spiked analyte
with expected concentrations.
Matrix effects
The matrix effects of the purified plasma were tested by
using a method defined by Bonfiglio et al. The post-


























Figure 1 Investigation of matrix effects by the post column infusion m
infusion system B: Total ion chromatogram C: Overlay chromatograms sho
angiotensin II.The isolated sample was injected onto column and the
gradient program was started, while angiotensin II was
being infused post column (concentration 1 μM) at a
flow rate 4 μl/min. The schematic post-column infusion
system is shown in Figure 1A.
Recovery
Recovery of angiotensin II was evaluated by comparison
of peak area of the isolated stable isotope labeled angio-
tensin II with standard prepared in 0.1% formic acid at
the concentrations of the quality controls representing
100% recovery. Recovery was analysed at four concentra-
tion levels corresponding to the quality controls in tripli-
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ethod defined by Bonfiglio et al. A: Scheme of the post-column
wing the matrix effects due to purified plasma on the detection of
























Figure 2 Overview about sample preparation for the quantification of angiotensin II.
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The endogenous levels of angiotensin II in human
plasma were tested in 9 healthy subjects and CKD-5D
patients. Stable isotope (13C- and 15 N-) labeled angio-
tensin II at a concentration of 200 pM was used as an
internal standard. The quantities of the native angioten-
sin II were calculated using the peak-area ratio of native
angiotensin II/stable isotope (13C- and 15 N-) labeled
angiotensin II (internal standard) multiplied by the abso-





























Figure 3 Detection of native angiotensin II by ESI-MS A: positive full
523.8 m/z. The b6 fragment ion (784.4 m/z) was used for the quantificatioStatistics
All results are presented as means ± SEM. Statistical sig-
nificance was determined by use of Mann–Whitney-test.
Results and discussion
In this study a new method was developed and validated
for the absolute quantification of endogenous angioten-
sin II levels in human plasma, since recent studies dem-
onstrated the insufficient specificity of the monoclonal











scan spectrum B: positive MS/MS spectrum of the parent ion
n.
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were extracted by using mixed-mode anion exchange
and reversed phase (MAX) solid phase extrac-
tion (SPE) cartridges, followed by an immunoaffinity-
purification. The purified samples were separated by
using reversed-phase chromatography and analyzed by
ESI-MS in fragmentation mode. The schematic overview
of the sample preparation is shown in the Figure 2. Since
the AQUA strategy was used for absolute quantification
of the native angiotensin II in human plasma, we decided
to isolate and fragment both the native and stable isotope
labeled peptide in the same scan. Due to “scan to scan”
variation of the electrospray ionisation, the detection of
both peptides within the same scan improves the preci-
sion and accuracy of the method significantly. The frag-
mentation of both peptides revealed predominantly one
intense ion corresponding to the b6-fragment of the
angiotensin II, which could be stable detected inde-
pendent of the concentration. Therefore, only this ion
was used for the quantification. The isolation window
of 526.3 ± 6 m/z was found to be optimal for the detec-
tion of both fragment ions: 784.4 m/z and 794.4 m/z of
native angiotensin II and the internal standard respect-



























Figure 4 Detection of stable isotope labeled angiotensin II by ESI-MS
parent ion 528.8 m/z. The b6 fragment ion (794.4 m/z) was used for the qextensive purification based on solid phase extraction
and immunoaffinity-purification, the analysis of the result-
ing fractions revealed low background.
Selectivity
The selectivity for the stable isotope (13C- and 15 N-) la-
beled angiotensin II was determined by comparison of
quality controls and plasma samples. The retention time
for angiotensin II was 12.1 min. No interfering peaks in the
purified plasma samples were observed at the retention
time of angiotensin II in the respective extracted ion chro-
matogram (data not shown).
Detection limit and the calibration range of the stable
isotope labeled (13C- and 15 N-) angiotensin II
The linearity range of the native angiotensin II was
determined using plasma spiked with stable isotope
(13C- and 15 N-) labeled angiotensin II. The six-point
calibration curve of stable isotope (13C- and 15 N-) la-
beled angiotensin II showed a reliable reproducibility in
the concentration range from 6 to 240 pM. The calibra-
tion curve was prepared by plotting peak-area ratio stable
isotope (13C- and 15N-) labeled angiotensin II/native










A: positive full scan spectrum B: positive MS/MS spectrum of the
uantification.































Figure 5 Linear calibration curve for stable isotope labeled angiotensin II prepared in plasma (3–120 fmol on column; N = 3).
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The coefficient of determination r2 for validation was
found to be 0.999 (Figure 5). The detection limit was de-
termined to be 3 pM corresponding to the signal three
times higher than the noise. The lower limit of quantifi-
cation was determined to be 6 pM.
Precision and accuracy
The accuracies and precisions for both intra- and inter-
day measurements are presented in Table 2. The LLOD
at at 3 pM in biologic matrix (plasma) is in accordance
with the LOD-values in different biologic matrices (plasma,
urine) recently described in the literature [15,16]. The
mean analytical intra- and inter-day precisions were found
to be between 4.6% and 16.0%. The intra- and inter-day
accuracies were between 91.5% and 112.5%.
Matrix effects
The investigation of the matrix effects using post-column
infusion of the native angiotensin II revealed no significant
suppression, but slight enhancement of the angiotensin II
signal around the specific retention time. Only a slight de-
crease in the mass peak intensity was detected at 4 min,Table 2 Accuracy and precision of quality control samples
I
QC Concentration (nM) Accuracy (




1calculated as (mean determined amount/nominal amount × 100).
2calculated as % CV. (SD/mean) × 100.which was most likely due to residual salts not retained by
the column (Figure 1B). Figure 1C shows matrix effects
chromatogram, overlaid by chromatogram of angiotensin II
standards prepared in 0.1% formic acid to indicate the elu-
tion profile for the analyte over the infusion matrix effect
baseline.
Recovery rate
The mean recovery rate was found to be 34.0 ± 2.3% and
the recovery rate was sufficient to quantify angiotensin
II in the determined calibration range.
Method application
The new method was applied for quantification of angio-
tensin II levels in plasma from healthy volunteers and
CKD-5D patients. The identity of the native angiotensin
II was confirmed using both the retention time and the
fragment ion from the co-eluting stable isotope labeled
internal standard (Figure 6). The native angiotensin II
was found in all plasma samples. Extracted ion chro-
matograms were generated and the analyte peaks inte-
grated. The quantitative levels of the native angiotensin
II were calculated using peak-area ratio of endogenousntra-day (n = 3) Inter-day (n = 9)





Figure 6 Analysis of purified plasma sample from healthy volunteer by ESI-MS. A: extracted ion chromatogram of the ion 784.4 ± 0.5 m/z
corresponding to the native angiotensin II and a characteristic fragment spectrum with labeling of the b6-fragment (grey shaded area)
B: extracted ion chromatogram of the ion 794.4 ± 0.5 m/z corresponding to the stable isotope labeled angiotensin II and a characteristic fragment
spectrum with labeling of the b6-fragment (grey shaded area). Confirmation of the identity of the native ngiotensin II was performed by using both:
retention time and fragment ion of co-eluting stable isotope ngiote ngiotensin II.
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angiotensin II multiplied by the absolute concentration
of the internal standard. The means plasma angiotensin II
levels were found to be 18.4 ± 3.3 pM in healthy subjects
and 64.5 ± 32.4 pM in CKD-5D patients (each n =9) and
did not vary significantly between these both groups
(Table 3). However, due to the small sample size the result
might not be representative, thus of the impact of angio-
tensin II in the context of CKD should be verify within a
large scale clinical study.
An extensively validated method for determination of
the native angiotensin II in human plasma has beenTable 3 Endogenous ngiotensin II concentrations in 9 individ
Endogenous angiotensin
Group 1 2 3 4
Healthy subjects 30.2 9.7 19.2 9.5
CKD-5D patients 16.8 10.4 13.4 205.4developed within this study. The AQUA strategy was
used to successfully determine the absolute concentra-
tion of the native angiotensin II in plasma of healthy vol-
unteers and CKD-5D patients. The new assay is highly
selective, sensitive and reliable for the detection and
quantification of angiotensin II between 6 and 240 pM.
The analytical precisions and accuracies values are within
the acceptable range.
Ethical approval
This study was approved by the local ethic committee of
the University Essen (approval number: 08-3817).ual healthy subjects and CKD-5D patients
II concentrations [pM] in individual subjects
5 6 7 8 9 mean
10.2 33.5 24.9 22.7 6.6 18.5
260.4 8.4 14.3 6.3 45.4 64.5
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